BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) reported that its petition for rehearing and rehearing en banc was denied today by the U.S. Court of Appeals for the Federal Circuit. The Company filed the petition following the Court’s decision in September regarding the validity of United States Patent No. 5,061,722, a composition of matter patent for ALTACE® (ramipril). The decision applied the recent U.S. Supreme Court decision in the KSR International v. Teleflex case to invalidate the patent on the basis of obviousness. King is evaluating its remaining legal options with respect to the patent following today’s decision to deny the petition.
